Immunic to participate in investor and scientific conferences in february

New york , feb. 1, 2024 /prnewswire/ -- immunic, inc. (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor and scientific conferences in february: february 8: biocapital europe 2024 . daniel vitt, ph.d.

IMUX Ratings Summary

IMUX Quant Ranking